Professor Ahn Ji-young of the Department of Dermatology at the Medical Center presented the phase 3 clinical trial results of Dupixent at a news conference on Wednesday. Last December, Dupixent won approval from the Ministry of Food and Drug Safety for treating adult patients aged 18 years and ...
7. Silverberg JI, Guttman-Yassky E, Simpson EL, et al. 502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results. British Journal of Dermatology. 2024;190(Supplement_2):ii8-ii8....
The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® 300 mg weekly experienced significant improvements in signs and symptoms of ...
The FDA decision followed positive results drawn from the BOREAS and NOTUS trials, both of which evaluated dupilumab’s efficacy and safety profile among individuals with high exacerbation risk and evidence of type 2 inflammation as measured by blood eosinophil counts greater than or equal to 300 c...
The FDA decision followed positive results drawn from the BOREAS and NOTUS trials, both of which evaluated dupilumab’s efficacy and safety profile among individuals with high exacerbation risk and evidence of type 2 inflammation as measured by blood eosinophil counts greater than or equal to 300 ...
“We are highly encouraged by these remarkable results fromNOTUSshowing a 34% reduction in COPD exacerbations compared to placebo, confirming the unprecedented results from our first Phase 3 trial, BOREAS,” saidGeorge D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief...
For teens 12 to 17 years of age with moderate-to-severe eczema not adequately controlled with topical prescription treatments, significant results were seen 16 weeks after starting treatment. More teens saw clearer skin (24% vs. 2%) when compared to teens not receiving Dupixent. Nearly half of...
Clinical Response At Week 16 (SOLO 1, SOLO 2, And CHRONOS) The results of the DUPIXENT monotherapy trials (SOLO 1 and SOLO 2) and the DUPIXENT with concomitant TCS trial (CHRONOS) are presented in Table 10. Table 10: Efficacy Results of DUPIXENT with or without Concomitant TCS at Week ...
Results were encouraging. At 16 weeks for SOLO 1 and SOLO 2, 37% and 36%, respectively, of patients who received Dupixent 300 mg weekly, and 38% and 36% of those who received it every 2 weeks, achieved clearing or near-clearing of skin according to the IGA scale. (Compared to 10%...
investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expre...